Diabetic foot ulcers (DFUs) are serious complication of diabetes leading to significant morbidity and mortality. Mortality rates are estimated to be 5% in the first 12 months, and 5-year morality rates have been estimated at 42%. The standard practices in DFUs management include surgical debridement, dressings to facilitate a moist wound environment and exudate control, wound off-loading, vascular assessment, and infection and glycemic control. Even with this comprehensive approach, there is still a need to improve the DFUs outcomes. Several adjuvant therapies have been studied to reduce DFUs healing times and amputation rates. The emerging cellular and acellular therapies using various growth factors and cytokines have been found to be beneficial in improving wound healing rates albeit isolated reports. We carried out a systematic pilot study in 20 such DFU patients with the local injections of a well characterised API (active pharmaceutical ingredient) derived from mesenchymal stem cells and compared with those on normal saline injections. There were significant (P < 0.01) differences in both the Oswestry disability index and visual analogue scale over a period of six months at the site of DFU. No adverse event. Healing was maintained one year post trials. The use of a well characterised API derived from mesenchymal stem cells rather than stem cells per se can take the controversy away from using cells for therapeutic purposes.